Literature DB >> 18283578

Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years.

Aarne H Kivioja1, Carl Blomqvist, Kalevi Hietaniemi, Clement Trovik, Anders Walloe, Henrik C F Bauer, Peter H Jorgensen, Peter Bergh, Gunnar Follerås.   

Abstract

BACKGROUND: Giant cell tumors of bone rarely metastasize but often recur locally after surgery. There is limited knowledge about the risk of recurrence related to different types of treatment. PATIENTS AND METHODS: We analyzed factors affecting the local recurrence rate in 294 patients with giant cell tumors of the extremities using prospectively collected material from 13 centers. The median follow-up time was 5 (0.2-18) years.
RESULTS: A local recurrence was diagnosed in 57 of 294 patients (19%). The overall 5-year local recurrence rate was 0.22. Univariate analysis identified young age and intralesional surgery to be associated with a higher risk of recurrence. Based on multivariate analysis, the relative risk was 2.4-fold for intralesional surgery compared to more extensive operative methods. There was no correlation between tumor size, tumor extension, sex of the patient, tumor location, or fracture at diagnosis and outcome. In the subgroup of 200 patients treated with intralesional surgery, the method of filling (cement or bone) was known for 194 patients and was statistically highly significant in favor of the use of cement.
INTERPRETATION: Intralesional surgery should be the first choice in most giant cell tumors, even in the presence of a pathological fracture. After thorough evacuation, the cavity should be filled with cement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283578     DOI: 10.1080/17453670710014815

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  78 in total

1.  Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.

Authors:  Yu-Peng Liu; Kang-Hua Li; Bu-Hua Sun
Journal:  Clin Orthop Relat Res       Date:  2012-07-07       Impact factor: 4.176

2.  The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT.

Authors:  Wendi O'Connor; Megan Quintana; Scott Smith; Monte Willis; Jordan Renner
Journal:  J Radiol Case Rep       Date:  2014-06-30

3.  Clinical effects of three surgical approaches for a giant cell tumor of the distal radius and ulna.

Authors:  Jing Zhang; Yi Li; Dongqi Li; Junfeng Xia; Su Li; Shunling Yu; Yedan Liao; Xiaojuan Li; Huilin Li; Zuozhang Yang
Journal:  Mol Clin Oncol       Date:  2016-09-21

4.  Current status of bone cementing and bone grafting for giant cell tumour of bone: a systemic review.

Authors:  R Vaishya; A Pokhrel; A K Agarwal; V Vijay
Journal:  Ann R Coll Surg Engl       Date:  2019-02       Impact factor: 1.891

5.  Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.

Authors:  Ping Jiang; Xile Zhang; Weijuan Jiang; Na Meng; Abudureyimujiang Aili; Junjie Wang
Journal:  Cancer Biol Ther       Date:  2020-04-16       Impact factor: 4.742

6.  Joint preservation after extensive curettage of knee giant cell tumors.

Authors:  Miguel A Ayerza; Luis A Aponte-Tinao; German L Farfalli; Carlos A Lores Restrepo; D Luis Muscolo
Journal:  Clin Orthop Relat Res       Date:  2009-06-10       Impact factor: 4.176

7.  The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).

Authors:  Jennifer L Beebe-Dimmer; Karynsa Cetin; Jon P Fryzek; Scott M Schuetze; Kendra Schwartz
Journal:  Rare Tumors       Date:  2009-12-28

8.  High-Speed Burring with and without the Use of Surgical Adjuvants in the Intralesional Management of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis.

Authors:  H Algawahmed; Robert Turcotte; F Farrokhyar; M Ghert
Journal:  Sarcoma       Date:  2010-07-27

9.  Curettage of benign bone tumors without grafts gives sufficient bone strength.

Authors:  Takashi Yanagawa; Hideomi Watanabe; Tetsuya Shinozaki; Kenji Takagishi
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

10.  Treatment and outcome of giant cell tumors of the pelvis.

Authors:  Maurice Balke; Arne Streitbuerger; Tymoteusz Budny; Marcel Henrichs; Georg Gosheger; Jendrik Hardes
Journal:  Acta Orthop       Date:  2009-10       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.